炎症

为患者带来更好的治疗

挖掘全球创新资源

Omilancor

炎症

Omilancor is a novel gut-restricted small molecule investigational drug that targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway impacting the gastrointestinal tract. LANCL2 plays an important role in the immunoregulatory process. By activating the LANCL2 pathway and modulating the interactions between immunological and metabolic signals in immune cells, omilancor is designed to create a favorable regulatory microenvironment in the gut, decreasing the production of key inflammatory mediators and increasing anti-inflammatory markers in regulatory T cells (Treg) within the site of inflammation.

全球研发进展:

II期

中国临床试验启动时的研发进展:

III期

arrow-btn

NX-13

炎症

NX-13是通过一种首创性肠道限制性小分子在研药物,用于治疗溃疡性结肠炎(UC)和克罗恩病(CD)。NX-13能够作用于线粒体相关受体NLRX1靶点,具有调节免疫反应的能力。通过激活NLRX1通路,NX-13可以促进免疫细胞的自噬和氧化磷酸化,同时减少CD4+效应T细胞的分化、活性氧及炎性小体的形成和炎性细胞因子的产生。

全球研发进展:

I期

中国临床试验启动时的研发进展:

III期

arrow-btn